AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aurinia Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.49−0.02 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.20B
- P/E (TTM)
- 7.2
- Dividend yield
- –
Aurinia Pharmaceuticals Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $271.35M | $216.19M | $158.53M | $103.47M | $45.49M | $0 | $0 | $345.00K | – | – | 95.9% | +25.5% |
| License, collaboration and royalty revenue | $11.71M | $18.95M | $16.98M | $30.56M | $117.00K | – | – | – | – | – | 4.1% | -38.2% |
| License and collaboration revenue | – | – | – | $30.56M | $117.00K | $50.12M | $318.00K | $118.00K | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $263.84M | $210.10M | $157.96M | $102.46M | $45.49M | $0 | $200.00K | $345.00K | $300.00K | $0 | 93.2% | +25.6% |
| Japan | $19.21M | $25.04M | $17.56M | $31.48M | $0 | $50.00M | $0 | $0 | – | – | 6.8% | -23.3% |
| Canada | – | – | – | – | – | – | – | – | $0 | $55.00K | – | – |
| China | – | – | – | – | – | $118.00K | $118.00K | $118.00K | $118.00K | $118.00K | – | – |
| Switzerland | – | – | – | – | – | – | – | – | $2.00K | $0 | – | – |
| Other | – | $0 | $0 | $89.00K | $117.00K | $118.00K | $118.00K | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Aurinia Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.